LAUSANNE, Switzerland I April 2, 2025 I AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for ...

The data presented support use of MR vaccine at 6 months to protect young infants during measles outbreaks and in settings ...

New research findings provide solid evidence that annual COVID-19 vaccine booster doses continue to be advisable for certain ...

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver ...

Led by a team of distinguished toxicology experts, TriApex was thrilled to take part in this prestigious meeting, engaging in ...

As of December 31, 2024, LAVA had cash, cash equivalents, and investments of $76.6 million, compared to cash, cash equivalents, and investments of $95.6 million as of December 31, 2023. The Company ...

Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...

Q4 2024 Earnings Call Transcript March 20, 2025 Vaxart, Inc. beats earnings expectations. Reported EPS is $-0.05, ...

Mucormycosis, a fungus infection caused by Mucorales, has a high mortality rates in those with weakened immune systems and ...

SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the full year 2024.